Plus Therapeutics (PSTV) Stock Price, News & Analysis

Company Overview

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Key Stats

• Today's Range: $0.47 to $0.51
• 50-Day Range: $0.18 to $0.80
• 52-Week Range: $0.16 to $2.31
• Volume: 1.62 million shs
• Average Volume: 19.40 million shs
• Market Capitalization: $30.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.88
• Consensus Rating: Moderate Buy

Plus Therapeutics Stock Analysis - MarketRank™

Plus Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 493rd out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Plus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Plus Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Plus Therapeutics are expected to grow in the coming year, from ($2.30) to ($1.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Plus Therapeutics is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Plus Therapeutics is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Plus Therapeutics has a P/B Ratio of 9.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.10% of the float of Plus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Plus Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Plus Therapeutics has recently decreased by 50.27%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Plus Therapeutics does not currently pay a dividend.

Dividend Growth

Plus Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.10% of the float of Plus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Plus Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Plus Therapeutics has recently decreased by 50.27%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.02

News Sentiment

Plus Therapeutics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Plus Therapeutics this week, compared to 2 articles on an average week.

Search Interest

66 people have searched for PSTV on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.

MarketBeat Follows

17 people have added Plus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 183% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Plus Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.79% of the stock of Plus Therapeutics is held by insiders.

Percentage Held by Institutions

Only 3.28% of the stock of Plus Therapeutics is held by institutions.

PSTV Stock Analysis - Frequently Asked Questions

How have PSTV shares performed this year?

Plus Therapeutics' stock was trading at $1.15 at the beginning of the year. Since then, PSTV stock has decreased by 56.6% and is now trading at $0.4990.

How were Plus Therapeutics' earnings last quarter?

Plus Therapeutics, Inc. (NASDAQ:PSTV) released its quarterly earnings results on Thursday, August, 14th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.08. The company earned $1.39 million during the quarter, compared to analyst estimates of $1.08 million.

When did Plus Therapeutics' stock split?

Plus Therapeutics shares reverse split on the morning of Monday, May 1st 2023.The 1-15 reverse split was announced on Monday, May 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Plus Therapeutics' major shareholders?

Top institutional investors of Plus Therapeutics include Jane Street Group LLC (0.19%). Insiders that own company stock include Howard Clowes, Greg Petersen, Robert P Lenk, Marc H Hedrick and Andrew John Hugh Macintyr Sims.
View institutional ownership trends.

How do I buy shares of Plus Therapeutics?

Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Plus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Plus Therapeutics investors own include Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), NVIDIA (NVDA), Arista Networks (ANET), Broadcom (AVGO) and Adobe (ADBE).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PSTV
• CIK: 1095981
• Web: www.plustherapeutics.com
• Phone: 737-255-7194
• Fax: 858-450-4335
• Employees: 20
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Plus Therapeutics: $8.88
• High Price Target: $20.50
• Low Price Target: $3.00
• Potential Upside/Downside: +1,737.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.98 million
• Net Margins: -357.85%
• Pretax Margin: -357.85%
• Return on Equity: N/A
• Return on Assets: -117.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.26
• Quick Ratio: 1.03

Sales & Book Value

• Annual Sales: $5.82 million
• Price / Sales: 5.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.05 per share
• Price / Book: 9.66

Miscellaneous

• Outstanding Shares: 60,490,000
• Free Float: 60,012,000
• Market Cap: $29.22 million
• Optionable: Not Optionable
• Beta: 0.67